Larazotide (AT-1001): The Tight Junction Peptide

Larazotide acetate, developed as AT-1001 and later INN-202, is an orally administered peptide designed to regulate intestinal tight junctions. It is the most clinically advanced compound ever developed around intestinal permeability, and its outcome is directly relevant to how clinicians discuss that concept with patients.

This guide situates Larazotide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

Tight junctions and intestinal permeability

The intestinal epithelium forms a selective barrier. Individual epithelial cells are sealed to one another by tight junctions, protein complexes including occludin, claudins and zonula occludens proteins that regulate what passes between cells.

These junctions are dynamic, opening and closing in response to signals. Zonulin is a protein that increases tight junction permeability, and its release is triggered by stimuli including gliadin — the gluten fraction relevant to celiac disease — and certain bacteria.

Increased intestinal permeability is a well-documented finding in celiac disease and in inflammatory bowel disease. What remains genuinely debated is the direction of causation in most other conditions: whether increased permeability drives systemic disease, or whether it is a consequence of inflammation occurring for other reasons. The popular concept of "leaky gut" tends to assume the first without establishing it.

How larazotide works

Larazotide is a synthetic octapeptide that acts as a zonulin antagonist, blocking zonulin-mediated tight junction opening and thereby reducing paracellular permeability.

Its design has an elegant feature worth noting. It is taken orally and is intended to act locally within the intestinal lumen, at the apical surface of the epithelium — it is not meant to be absorbed. Minimal systemic absorption is a design goal rather than a limitation, which sidesteps the usual problem of oral peptide bioavailability entirely. The target is the surface the peptide is already sitting on.

The clinical concept was an adjunct for celiac patients: even careful gluten-free diets involve inadvertent exposure, and a drug that limits the permeability response to that exposure could reduce symptoms.

What the phase 3 trial found

Larazotide progressed through phase 2 work that generated genuine optimism, with some studies suggesting symptom improvement in celiac patients on a gluten-free diet.

It advanced to a phase 3 trial in celiac disease — and the trial did not meet its primary endpoint. Development in that indication was discontinued following an interim analysis.

How to read that result matters. It does not prove tight junction regulation is a worthless target, nor that intestinal permeability is unimportant in celiac disease. Trials fail for many reasons including endpoint selection, dosing, and population heterogeneity.

What it does establish is more specific and still important: the most rigorously tested permeability-targeting drug did not demonstrate benefit in the condition where permeability pathology is best characterized. Anyone extrapolating confidently from permeability biology to clinical benefit in less well-defined conditions should weigh that.

What this means clinically

Patients frequently arrive having read about leaky gut and asking about interventions targeting permeability, often including BPC-157, glutamine, or larazotide itself.

The accurate framing acknowledges the real science: tight junctions exist, permeability is measurable, and it is genuinely increased in specific documented conditions. It then adds the part usually omitted — that the best-developed drug for this target did not succeed in the best-characterized disease, and that permeability testing does not currently guide treatment in a validated way.

For celiac disease, the evidence-based intervention remains a strict gluten-free diet with dietetic support. Our leaky gut guide covers the broader concept, and larazotide is not FDA-approved for any indication.